As adjunctive treatment for bronchial asthma in patients aged 2 to 5 years with mild to moderate persistent asthma, insufficiently controlled by inhaled corticosteroids, and insufficient clinical control of asthma by short-acting β-adrenergic receptor agonists. As an alternative treatment instead of low doses of inhaled corticosteroids for patients 2 to 5 years of age with persistent mild asthma who have not observed any recent major seizures of bronchial asthma requiring oral corticosteroids, or who cannot use corticosteroids. Prevention of asthma, a dominant component of which is exercise-induced bronchospasm in patients 2 years of age and older. Relieving symptoms of seasonal and year-round allergic rhinitis.
Composition and form of release
Main active ingredient: montelukast.
Excipients: lactose (monohydrate), microcrystalline cellulose, sodium croscarmellose, hydroxypropyl cellulose, magnesium stearate, titanium dioxide, etc.
It is produced in the form of tablets, 10 mg of montelukast in each.
The specified drug belongs to the group of cystenyl-leukotriene receptor blockers, which play an important role in the development of broncho-obstructive syndrome.
As a result, the drug is effective in the treatment of obstructive diseases that develop in the lower parts of the respiratory system.
Montelukast, which is the main active ingredient of the drug, has the property, when applied, to bind to cystenyl-leukotriene receptors (CysLT1 receptors), which are responsible for the occurrence of bronchospasm, sputum secretion from the bronchi, and other symptoms accompanying obstructive bronchitis.
Capable of inhibiting bronchoconstriction in patients with asthma.
It has the property of stopping the arising bronchospasm at all stages of its development, due to the ability to reduce the body’s response to allergic antigens.
The use of montelukast leads to a decrease in the number of eosinophils in the airways.
This drug is used for the treatment of adults, as a drug for the additional treatment of bronchial asthma in patients with persistent asthma, both mild and moderate, including if they are not adequately controlled by inhaled GCS.
It is also effective if the patient has insufficient asthma control with short-acting β-agonists.
Also applicable for:
- symptomatic treatment of seasonal allergic rhinitis in patients with bronchial asthma;
- prevention of asthma, in which bronchospasm is provoked by physical exertion;
- relieve symptoms of seasonal and perennial allergic rhinitis.
You should not use the specified drug if the patient has had a previous hypersensitivity (allergy) with respect to one of the components that are part of the drug – both main and auxiliary.
In pediatrics, it is used from the age of 15.
Application during pregnancy and lactation
Treatment of pregnant women is carried out with every possible care, only for serious indications.
Breastfeeding should be suspended during treatment.
Method of administration and dosage
The drug is used for asthma and allergic rhinitis (both seasonal and year-round), 1 tablet 1 time per day.
In the treatment of asthma – in the evening, 1-2 hours after the evening meal. For the treatment of allergic rhinitis, the time of taking the drug can be selected on an individual basis.
The therapeutic effect occurs within 24 hours after application.
Do not use the drug at the same time as other medicines that contain montelukast.
Overdose with this drug does not cause any particular adverse events. In rare cases, the following were observed:
- drowsiness, psychomotor hyperactivity;
Symptomatic therapy is recommended.
Usually the drug is well tolerated. Side effects can occur only in rare cases. In particular, there may be observed:
- anaphylactic reactions, hypersensitivity reactions, including anaphylactic shock;
- upper respiratory tract infections;
- headache, abdominal pain, thirst, nausea, vomiting, dyspepsia;
- increased bleeding;
- sleep disturbances, nightmares, hallucinations, insomnia, irritability, anger, agitation, hostility, depression, disorientation, suicidal thoughts;
- lethargy, dizziness, paresthesia, hypersthesia, palpitations;
- hepatitis, increased levels of hepatic transaminases;
- arthralgia, myalgia, including muscle cramps;
- asthenia / fatigue, discomfort, swelling, fever;
- nose bleed.
Storage conditions and periods
This medicinal product is able to retain its medicinal properties for 3 years from the production date indicated on the package.
The drug should be kept out of the reach of children. Storage temperature should not exceed 30 ° C.